Q3 EPS Estimates for NeoGenomics Raised by Leerink Partnrs

NeoGenomics, Inc. (NASDAQ:NEO) – Equities researchers at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for shares of NeoGenomics in a report released on Tuesday, February 18th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $0.00 per share for the quarter, up from their previous forecast of ($0.01). The consensus estimate for NeoGenomics’ current full-year earnings is ($0.05) per share. Leerink Partnrs also issued estimates for NeoGenomics’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.04 EPS and FY2027 earnings at $0.28 EPS.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). The firm had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%.

Several other analysts have also recently issued reports on NEO. The Goldman Sachs Group lowered their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Needham & Company LLC lowered their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday. Bank of America lowered their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday. Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Jefferies Financial Group initiated coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price target for the company. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, NeoGenomics currently has an average rating of “Moderate Buy” and a consensus target price of $19.80.

NeoGenomics Stock Down 6.8 %

Shares of NASDAQ NEO opened at $11.86 on Friday. NeoGenomics has a 52-week low of $10.69 and a 52-week high of $19.11. The firm has a fifty day moving average of $15.28 and a 200-day moving average of $15.49. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91.

Hedge Funds Weigh In On NeoGenomics

A number of institutional investors have recently added to or reduced their stakes in NEO. SBI Securities Co. Ltd. acquired a new position in NeoGenomics in the 4th quarter worth $26,000. Versant Capital Management Inc lifted its holdings in NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after buying an additional 1,142 shares in the last quarter. Quarry LP acquired a new position in NeoGenomics in the 3rd quarter worth $40,000. Blue Trust Inc. lifted its holdings in NeoGenomics by 42.3% in the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after buying an additional 987 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its holdings in NeoGenomics by 788.7% in the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company’s stock worth $61,000 after buying an additional 3,289 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.